Searched for
DRUG MAJOR
Dabur India shares in focus after US FDA places drugs from Silvassa plant under import alert. Here’s whyDabur India shares are set to be in focus after the US FDA issued an import alert on drugs manufactured at its Silvassa plant, citing data ...- States must leverage trade pacts to attract investment: PM ModiPrime Minister Narendra Modi encouraged regional leaders to enhance trade collaborations and simplify business operations, stressing the ne...
- Manipur CM Yumnam Khemchand Singh says 11,000 violence-hit families resettled with Centre’s helpManipur has resettled 11,000 families affected by violence. Chief Minister Yumnam Khemchand Singh shared this progress at a NITI Aayog meet...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Saudi Arabia lifts 5-year ban on Lebanese imports, marking a thaw in Gulf-Lebanon tiesAfter a five-year hiatus, Saudi Arabia is reopening its market to Lebanese imports, a decision that stemmed from previous drug smuggling ap...
- Market Trading Guide: Akums Drugs among 4 stock recommendations for ThursdayDomestic equities ended lower amid global uncertainty and caution ahead of key US inflation data. Despite market weakness, analysts remain ...
- Claude Fable 5 & Mythos 5: Key highlights from Anthropic’s latest launchAnthropic has launched Claude Fable 5, its most capable publicly available AI model, excelling in complex tasks and benchmarks. Alongside i...
- Hetero partners with Richter to develop, market Semaglutide injection globallyHyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...
- Neeraj Sharma case: How fake job offers triggered major H-1B visa fraud probe in the USUS H1-B visa fraud: A major US immigration fraud probe targets 17 naturalised citizens. Neeraj Sharma, an Indian-origin CEO, faces denatura...
- AI saves clinicians time but most lack training, survey findsArtificial intelligence is helping doctors and nurses save time and see more patients. However, a Philips survey shows most healthcare work...
- US stocks: US market rises as tech shares gain, Middle East tensions easeWall Street indexes opened higher on Tuesday, driven by a second consecutive day of gains for chipmakers. Easing Middle East tensions also ...
- US stocks | Alphabet taps Intel to make three million in-house chips: ReportNvidia has not placed an order with Intel yet, but has been evaluating whether the company's technology can be used to make a processor tha...
- US stocks today: US market gains as semiconductor stocks rebound, Middle East tensions easeMajor Wall Street indexes saw a strong rebound. This recovery was driven by gains in chip stocks. Signs of de-escalation in Middle East ten...
- Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefitsEli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...
- India’s rising export champion faces a critical credibility testIndia's seafood exports are soaring, reaching record highs and aiming for $30 billion within five years. Despite overcoming US tariffs and ...
- Banned substance in shrimp: Vet shops under close watchIndia's top drug regulator is cracking down on veterinary shops. This action follows a significant rejection of shrimp exports to major mar...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- AI-Powered drug discovery could transform treatment development for Alzheimer’s, Parkinson’s and other brain disorders.Researchers are increasingly using AI to accelerate the search for treatments for neurological conditions such as Alzheimer’s, Parkinson’s,...
- FDA approval puts Wockhardt’s Zaynich in $9 billion antibiotics marketWockhardt's new antibiotic, Zaynich, has received US FDA approval. This drug uses a novel mechanism to fight drug-resistant bacteria. It ta...
- Wockhardt secures US FDA approval for antibiotic ZaynichWockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. Thi...
Load More
